Management of Prostatodynia in Younger Patients With Non-ablative Erbium:YAG Intraurethral Laser
CompletedNot applicableNCT04446598
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This prospective study aimed to compare the clinical outcomes between the use of the erbium: YAG (Er:YAG) laser, intraurethrally administered in long non-ablative SMOOTH™ train of pulses applied at the level of the male prostatic urethra, to the use of the pharmacological treatment of oral tadalafil for the treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). The results show that both treatments are effective in alleviating symptoms of CP/CPPS. The non-ablative Er:YAG SMOOTHTM laser seems to be a promising treatment for this widely spread condition. More studies are needed to confirm its safety and efficacy.
Study details
- Official title
- Non Ablative Erbium:YAG Laser Transurethral Treatment for Chronic Prostatitis/Chronic Pelvic Pain Syndrome in Younger Patients: a Prospective Comparative Study
- Conditions
- Interventions
- Device: non-ablative SMOOTH mode Erbium YAG laser
- Drug: Tadalafil 5mg
- Sponsor
- Adrian Gaspar
- Organization
- Espacio Gaspar Clinic
- Start date
- 2017-03-13
- Primary completion
- 2018-11-30
- Sex
- Male
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Argentina
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * clinical diagnosis of chronic prostatitis/chronic pelvic pain syndrome with characteristic symptoms of perineal pain and urinary symptoms of dysuria and urinary frequency; * negative urine culture after prostatic massage; prostatic volume less than 50 cc in prostatic ultrasound; * obstructive uroflowmetric pattern with a Q-max value between 10 and 15 ml/sec Exclusion Criteria: * age over 50 years * current or recent (last 6 months) pharmacological or other therapies of CP/CPPS
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04446598